Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Metabolic |
| Evidence grade | A Human trial evidence |
| Regulatory status | Approved outside the US |
| Human amounts | Trial dosesDosing reference Study durations |
| Format | Lyophilized vial |
| Type | Single compound |
| Molecular formula | C207H317N45O65 |
| Molecular weight | 4,476 g/mol |
| CAS number | 2259884-03-0 |
| Sequence | Not listed |
| References | 15 |
| Summary | Mazdutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. It was approved in China in June 2025 for long-term weight management and in September 2025 for glycaemic control in type 2 diabetes, and it remains investigational in the United States, where phase 2 trials have been run. Randomized trials have reported body-weight and HbA1c reductions versus placebo or dulaglutide, with gastrointestinal events the most common adverse events; this entry summarizes them for research reference only. |